The United States attacked Iran without consulting its European allies. President Donald Trump assumed the operation would be a quick win, over before anyone had to take a position. Instead, Washington answered a question Western governments had long avoided. After years of pushing Nato towards confrontation with China, would the transatlantic alliance fight a war it had not chosen together? The a...
The United States attacked Iran without consulting its European allies. President Donald Trump assumed the operation would be a quick win, over before anyone had to take a position. Instead, Washington answered a question Western governments had long avoided. After years of pushing Nato towards confrontation with China, would the transatlantic alliance fight a war it had not chosen together? The answer was no. Iran and Taiwan are different cases. One sits on Europe’s wider periphery and carries...
seb_ra/iStock via Getty Images Viridian Therapeutics Overview Viridian Therapeutics, Inc. ( VRDN ) shares closed about 32% lower on Monday. As you’re aware, they announced the Phase 3 REVEAL-1 topline results for Elegrobart. However, even though they framed it as a positive outcome, there were a few things investors clearly didn’t like. Overall, the trial did meet its primary endpoint; we saw stat...
seb_ra/iStock via Getty Images Viridian Therapeutics Overview Viridian Therapeutics, Inc. ( VRDN ) shares closed about 32% lower on Monday. As you’re aware, they announced the Phase 3 REVEAL-1 topline results for Elegrobart. However, even though they framed it as a positive outcome, there were a few things investors clearly didn’t like. Overall, the trial did meet its primary endpoint; we saw statistically significant improvement in proptosis, but I think investors had been expecting a much stronger, more clearly differentiated efficacy profile here. Diplopia resolution was also better than placebo, particularly in the Q4W arm, but results across dosing regimens were a bit mixed, as I'll explain. My view here would be a very cautious hold, in the sense that the core story does still remain intact. We have to consider that Elegrobart is clearly efficacious with a differentiated subcutaneous profile, and coupled with Veligrotug, still supports a potential TED franchise. But the REVEAL-1 data has taken a big hit on market confidence in some, who no longer view it as a true best-in-class, market-dominating outcome. Which means we need to take a more balanced stance before buying in on this dip. I think what investors should consider now is that focus shifts to the REVEAL-2, in chronic TED readout, the Veligrotug PDUFA outcome, and commercial differentiation. These will ultimately determine if Viridian can still drive meaningful market share despite a less clean efficacy profile. Elegrobart Overview Just to give a bit of background, Viridian’s drug candidate, Elegrobart, is a next-generation monoclonal antibody. Its goal is to target the insulin-like growth factor-1 receptor (IGF-1R), which is a pretty well-validated driver of thyroid eye disease (TED). So, mechanistically speaking, we usually see IGF-1R is overexpressed on orbital fibroblasts in TED, which then forms a signaling complex with the TSH receptor. Now, the activation of this pathway is what drives inflammati...
designer491/iStock via Getty Images Motio Research reports their initial estimate of U.S. median household income for February 2026 is $87,630, a $360 (or 0.4%) increase from their initial January 2026 estimate of $87,270 . The firm's estimates are based on income data collected by the U.S. Census Bureau through its monthly Current Population Survey. This survey is conducted during the week contai...
designer491/iStock via Getty Images Motio Research reports their initial estimate of U.S. median household income for February 2026 is $87,630, a $360 (or 0.4%) increase from their initial January 2026 estimate of $87,270 . The firm's estimates are based on income data collected by the U.S. Census Bureau through its monthly Current Population Survey. This survey is conducted during the week containing the 12th day of the month following the month in which its data applies. Motio Research adjusts its raw monthly estimates to account for the effects of seasonality and inflation, presenting its results in the form of an index with the median household income of January 2010 assigned a value of 100. The initial value of the firm's U.S. Real Median Household Income Index for February 2026 is 119.2. The following screenshot of Motio Research's interactive chart shows how this index has changed from January 2010 through February 2026: Motio's survey-based estimates indicate the pace of growth of median household income has slowed since the end of 2025. The cash and free travel incentives the Trump administration offered to illegal immigrants likely contributed to the exit of large numbers of the lowest income earners in this demographic, whose departure effectively boosted the nation's median household income. Analyst's Notes Political Calculations produces median household income estimates using other original data sources that complement Motio Research's survey-based estimates. Because of the ongoing delays in official aggregate wage and salary data being reported, we'll present our estimate for January 2026 in this edition. We expect to fully catch up with Motio Research's estimates with our February and March 2026 estimates in early May 2026, when the wage and salary data for both will become available. Political Calculations' official estimate for median household income in January 2026 is $86,506, which is $575 (or 0.67%) higher than the $85,931 we projected for Dece...
NEW PORT RICHEY, Fla., April 01, 2026 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”) , a provider of residential solar and commercial long-duration energy-storage solutions, today reported financial results for the fourth quarter and twelve months ended December 31, 2025.
NEW PORT RICHEY, Fla., April 01, 2026 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”) , a provider of residential solar and commercial long-duration energy-storage solutions, today reported financial results for the fourth quarter and twelve months ended December 31, 2025.
BOISE, Idaho, April 01, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq:MU), (the "Company" or "Micron") announced today that the previously announced cash tender offers (each, a “Tender Offer” and, collectively, the “Tender Offers”) to purchase any and all of Micron’s senior notes listed in the table below (collectively, the “notes”) expired at 5:00 p.m., New York City time, on March 31,...
BOISE, Idaho, April 01, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq:MU), (the "Company" or "Micron") announced today that the previously announced cash tender offers (each, a “Tender Offer” and, collectively, the “Tender Offers”) to purchase any and all of Micron’s senior notes listed in the table below (collectively, the “notes”) expired at 5:00 p.m., New York City time, on March 31, 2026 (the “Expiration Time”). As of the Expiration Time, the aggregate principal amount of each ser
One of the largest players in Mexico’s booming pension fund system is eyeing more investments in the country’s financial sector after purchasing a stake in Citigroup Inc. ’s retail bank Grupo Financiero Banamex. Afore Sura, the third largest pension manager in the country — overseeing 1.4 trillion pesos ($81.8 billion) — says there’s potential to put money into the sector even as fintech startups ...
One of the largest players in Mexico’s booming pension fund system is eyeing more investments in the country’s financial sector after purchasing a stake in Citigroup Inc. ’s retail bank Grupo Financiero Banamex. Afore Sura, the third largest pension manager in the country — overseeing 1.4 trillion pesos ($81.8 billion) — says there’s potential to put money into the sector even as fintech startups encroach on traditional players’ territory and force them to slash fees, said Andres Moreno , chief investment officer for the fund. “Mexican banking is still profitable, even while facing a decline in commissions and other headwinds that have to play out,” Moreno said in an interview in Mexico City. The sector, he added, is undervalued compared to peers in Latin America and has low penetration. It “represents an opportunity.” Afore Sura was the only local pension fund to participate in the sale of Banamex, buying a portion of a 24% stake in February. The transaction, which has yet to close, was announced by Citi as part of a move to sell stakes under 5% in the Mexican lender following the sale of a majority to billionaire Fernando Chico Pardo . In addition to its recent bet in traditional banking, the pension fund has also invested in fintechs such as Klar , and participated in a lending facility to SME-lender Konfio, Moreno added. He declined to name other deals before they have advanced further. Competition is ramping up in Mexico’s banking sector as legacy banks and fintechs alike vie for customers in a country where data shows nearly half of adults don’t have a bank account. Still, several of the country’s publicly traded banks, such as Grupo Financiero Banorte SAB de CV and Gentera SAB de CV, trade below global peers, Bank of America strategists wrote in March. Rating agencies including Fitch have cautioned that risks for the industry include slowing credit growth, increases in delinquencies, and uncertainty around North America’s existing trade agreement, the USMCA. ...
With much of a person's Social Security benefit depending on their earnings record, spousal benefits allow people with shorter or spotty work histories to still reap some benefits from the program. By claiming Social Security spousal benefits , you're eligible to receive up to 50% of the primary claiming spouse's primary insurance amount (their monthly benefit when claiming at their full retiremen...
With much of a person's Social Security benefit depending on their earnings record, spousal benefits allow people with shorter or spotty work histories to still reap some benefits from the program. By claiming Social Security spousal benefits , you're eligible to receive up to 50% of the primary claiming spouse's primary insurance amount (their monthly benefit when claiming at their full retirement age ). It might not be the best route for all married retirees, but it's a strategy worth considering. If you find yourself debating whether to go the spousal benefits route, below are three things to know beforehand. Continue reading
The FDA's fast-track nicotine pouch approval plan is running into resistance because regulators and outside critics are still uneasy about the science and the possibility of creating new nicotine users, especially among young people, according to Reuters. After the pilot was launched under pressure to speed reviews, the agency has reportedly not fully resolved whether it has enough evidence to bal...
The FDA's fast-track nicotine pouch approval plan is running into resistance because regulators and outside critics are still uneasy about the science and the possibility of creating new nicotine users, especially among young people, according to Reuters. After the pilot was launched under pressure to speed reviews, the agency has reportedly not fully resolved whether it has enough evidence to balance public-health benefits for adult smokers against youth-addiction risks. Of concern, the scientific evidence for speeding them through was not as clear-cut as was originally anticipated. Notably, pouches are the fastest-growing tobacco category in the U.S., which is a major reason why companies want quicker authorization and why the FDA is being pushed to move faster. However, advocacy groups continue to warn that easier access could widen nicotine use among teens. The FDA pilot was designed to fast-track pouches from Philip Morris ( PM ), Altria ( MO ), British American Tobacco's ( BTI ) Reynolds American, and Turning Point Brands ( TPB ). More on the tobacco sector British American Tobacco: The Ideal Defensive Asset With A 12x P/E British American Tobacco: Nicotine Pouches/Vapour Tailwinds Entering FY2026 - Rich Dividend Yields Altria Group's Market Share Continues To Be A Thorn In The Side Philip Morris updates on its 'industry-leading shift' away from cigarettes Altria Group slides for the seventh straight session
Medtronic wins FDA's approval for Stealth AXiS in cranial & ENT, expanding its AI-driven surgical platform after spine clearance and boosting growth prospects.
Medtronic wins FDA's approval for Stealth AXiS in cranial & ENT, expanding its AI-driven surgical platform after spine clearance and boosting growth prospects.